Nov 22, 2022 / 09:30PM GMT
Operator
Good afternoon, ladies and gentlemen. Welcome to the Arvinas conference call. (Operator Instructions) I would now like to turn the conference over to your speaker, Jeff Boyle, Vice President, Investor Relations at Arvinas. You may begin.
Jeff Boyle - Arvinas, Inc. - VP of IR
Thank you, and good afternoon, everyone, and thank you for joining us to discuss the ARV-471 Phase II VERITAC data. This morning, we issued a press release highlighting data, which can be accessed in the Investors section of our website at arvinas.com. With me today are our Arvinas President and Chief Executive Officer, John Houston; and Arvinas Chief Medical Officer, Ron Peck. Chris Boshoff, Pfizer's Chief Development Officer, Oncology and Rare Disease, Pfizer Global Product Development, will join for the Q&A portion of the call.
Before we begin the call, I'd like to remind you today that today's discussion will contain forward-looking statements that involve risks and uncertainties. These risks and uncertainties are outlined on Page 2 of this presentation and in the company's
Arvinas Inc SABCS Event Transcript
Nov 23, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers